Treatment & Procedure
CBT-I – cognitive behavioral therapy for insomnia (KVT-I)
Biohacking
Anyone who has been sleeping badly for months often reaches for pills, melatonin or sleep gadgets. The best-supported treatment does without all of that: cognitive behavioral therapy for insomnia, CBT-I for short (KVT-I in German). It works with sleep pressure, the link between bed and lying awake, and the thoughts that circle at night. The first weeks are demanding, but the effect lasts a long time.
In short
CBT-I combines several components: sleep restriction, stimulus control, work on ruminating thoughts, sleep hygiene and relaxation. In a meta-analysis of 20 randomized trials with 1,162 adults, those treated fell asleep around 19 minutes faster and lay awake around 26 minutes less at night, and in a further analysis the advantage lasted up to a year. The European insomnia guideline recommends CBT-I as the first treatment for adults of all ages, in person or digitally; in Germany, digital programs are available on prescription as DiGA (digital health applications). The limits: total sleep time barely increases, and in the first weeks sleep restriction makes you measurably more tired.
What CBT-I is and how it works
CBT-I is not a single trick, but a program over a few weeks, with a therapist, in a group or as a digital program. The studies only count as CBT-I what combines at least three of these components: cognitive therapy, stimulus control, sleep restriction, sleep hygiene and relaxation.
In sleep restriction, the time in bed is first limited to the time you actually sleep and then gradually extended as soon as sleep becomes more consolidated. This builds up sleep pressure. Stimulus control links the bed back to sleeping: only go to bed when you are tired, get up when you lie awake for a long time, fixed wake-up time. The cognitive work addresses worries and expectations that prolong lying awake, such as the thought that without eight hours of sleep the next day is lost. Sleep hygiene and relaxation complement this, but are not enough on their own; more on this on the pages on sleep and sleep hygiene and the evening routine.
What is well supported
CBT-I is one of the best-studied treatments in sleep medicine. The meta-analyses show faster sleep onset, less lying awake at night and higher sleep efficiency, and the effect lasts for months. In direct comparison with sleeping pills, it is superior in the long term. That is why the American College of Physicians has recommended CBT-I as the first treatment for all adults with chronic insomnia since 2016, and the European guideline of 2023 does so with the highest grade of recommendation – for adults of all ages, including those with comorbidities, in person or digitally.
The digital form is also well studied. Fully automated programs without therapists clearly improved the severity of insomnia in 15 randomized trials with 3,507 participants.
What the studies show
Trauer 2015 — meta-analysis of 20 trials
20 randomized trials with 1,162 adults with chronic insomnia without accompanying physical, mental or other sleep disorders, in-person CBT-I against inactive control. After treatment, sleep onset latency shortened by 19 minutes, lying awake at night by 26 minutes, and sleep efficiency rose by 9.9 percentage points. Total sleep time increased by only 7.6 minutes, not significantly. The effects appeared to be maintained at later time points; side effects were not reported.
van der Zweerde 2019 — what remains after one year
30 randomized trials with follow-up. For insomnia severity, the effect size was 0.64 after three months, 0.40 after six months and 0.25 after twelve months. The effect becomes smaller over time, but remains clinically meaningful for up to a year.
Mitchell 2012 — therapy against pill
A systematic review of five randomized trials that compared CBT-I directly with sleeping pills, including benzodiazepines and Z-drugs such as zopiclone. In the long term, CBT-I was superior, with low to moderate quality of evidence; in the short term, benzodiazepines worked faster, with very low quality of evidence.
Gao 2026 — digital programs
15 randomized trials with 3,507 adults on fully automated digital programs. Insomnia severity fell clearly, standardized mean difference minus 0.82; sleep onset and sleep efficiency also improved. Newer trials tended to find smaller effects, and there are only a few trials on app programs so far.
Kyle 2014 — why the start makes you tired
16 patients with insomnia in the sleep laboratory during four weeks of sleep restriction. Measured sleep time fell by 69 to 91 minutes per night in the first weeks, and daytime sleepiness and lapses in the reaction test increased. After three months, sleepiness and reaction time were back at baseline, and the insomnia symptoms were clearly better. There was no control group.
Where the data stop
CBT-I mainly improves how quickly you fall asleep, how long you lie awake at night and how you experience sleep. Total sleep time barely increases in the studies. Anyone hoping for more hours of sleep should know this. The effect wanes over time, and the large meta-analysis of 2015 excluded people with accompanying physical, mental or other sleep disorders.
For the digital programs, the effects in newer trials are smaller than in older ones, and there are only a few trials on pure app programs so far. Finally, adverse effects are hardly recorded systematically: of 99 randomized trials, only 32 addressed them at all, and only 7 reported them completely.
Status, approval and legal
CBT-I is not a medicine, but a psychotherapeutic procedure. The European Insomnia Guideline 2023 and the American College of Physicians recommend it as the first treatment for chronic insomnia; according to the European guideline, sleeping pills only come into question if CBT-I does not work sufficiently, and mostly only in the short term.
In Germany, CBT-I is offered in psychotherapy and sleep medicine and as a digital health application (DiGA), an app that doctors can prescribe. In the BfArM’s DiGA directory, programs are listed for the diagnoses nonorganic insomnia (F51.0) and disorders of initiating and maintaining sleep (G47.0); they can be prescribed by doctors or psychotherapists. Which program comes into question is shown in the directory.
Safety
CBT-I has no drug risks, but it is not entirely free of side effects. In the initial phase of sleep restriction, sleep time falls, and daytime sleepiness and reaction time worsen measurably; this settles within weeks. During this phase, caution is advisable when driving and with work involving a risk of accidents.
Poor sleep does not always have a psychological cause. If another sleep disorder is suspected, such as sleep apnea or movement disorders during sleep, the European guideline recommends an examination in the sleep laboratory. Anyone already taking sleeping pills should clarify a change with the prescribing doctor.
BK-Score Well supported
| Human evidence | 9 | |
|---|---|---|
| Mechanism | 7 | |
| Safety data | 6 | |
| Hype gap | 8 | |
| Track record of use | 9 |
Evidence 9, because numerous randomized trials and meta-analyses are available: in 20 trials with 1,162 adults, those treated fell asleep around 19 minutes faster and lay awake around 26 minutes less at night (Trauer 2015), the advantage lasted up to a year in 30 trials (van der Zweerde 2019), and digital programs worked clearly in 15 trials with 3,507 participants (Gao 2026). Mechanism 7, because the components target well-understood levers – sleep pressure through limited time in bed, decoupling of bed and lying awake, less rumination –, but it is open which component contributes how much in whom. Safety 6, because the temporary daytime sleepiness and poorer reaction time in the initial phase of sleep restriction have been measured (Kyle 2014), but side effects are only rarely recorded systematically in the trials: of 99 randomized trials, only 7 met all criteria for complete reporting (Condon 2021). Hype 8, because the expectation “sleep better without pills” is covered by the data; only total sleep time barely increases, which is rarely mentioned in the promotion. Use 9, because the method has been used for decades in sleep medicine and psychotherapy and is recommended as the first treatment in Europe and the USA (Riemann 2023, Qaseem 2016). Direction positive. For comparison: sleep apnea therapy with CPAP (9/9/9/4/9) as a similarly well-supported sleep treatment, zopiclone (7/8/8/6/9) as a sleeping pill with short-term effect, sleep and sleep hygiene (7/7/7/5/10) as an everyday building block.
The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)
Frequently asked questions about CBT-I
What is CBT-I?
Cognitive behavioral therapy for insomnia, KVT-I in German. It combines sleep restriction, stimulus control, work on ruminating thoughts, sleep hygiene and relaxation into a program over a few weeks. Guidelines in Europe and the USA recommend it as the first treatment for chronic insomnia.
Is CBT-I better than sleeping pills?
In the long term yes, according to a review of direct comparison studies. In the short term, benzodiazepines work faster. The effect of CBT-I lasts after the end of treatment, in studies up to a year.
Does CBT-I also work as an app?
Yes. Fully automated digital programs clearly improved the severity of insomnia in 15 randomized trials with 3,507 participants. In Germany, programs are available as a digital health application on prescription, listed in the BfArM’s DiGA directory.
Why am I more tired at the start of CBT-I?
Sleep restriction limits the time in bed in order to build up sleep pressure. In a laboratory study, sleep time fell by 69 to 91 minutes in the first weeks, and sleepiness and reaction time worsened. After three months, this was back at baseline.
Will I sleep longer with CBT-I?
Hardly. In the large meta-analysis, total sleep time increased by just under eight minutes. What improved clearly were sleep onset latency, lying awake at night and sleep efficiency, that is the proportion of time in bed during which you sleep.
Related
- Related topicSleep & sleep hygiene
- Related topicOrexin receptor antagonists (daridorexant, suvorexant, lemborexant)
- Same sectionNeurofeedback (EEG biofeedback)
- Same sectionCPAP for sleep apnea
- Same sectionChronic pain
- Same sectionFaecal microbiota transplantation (FMT)
Sources
- Trauer et al., Ann Intern Med 2015 (meta-analysis, 20 randomized trials)
- van der Zweerde et al., Sleep Med Rev 2019 (long-term effects, 30 trials)
- Mitchell et al., BMC Fam Pract 2012 (CBT-I versus sleeping pills)
- Gao et al., Sleep Breath 2026 (fully automated digital CBT-I, meta-analysis)
- Kyle et al., Sleep 2014 (sleep restriction: sleepiness and reaction time)
- Condon et al., Sleep Med Rev 2021 (recording of adverse effects)
- Riemann et al., J Sleep Res 2023 (European insomnia guideline)
- Qaseem et al., Ann Intern Med 2016 (guideline of the American College of Physicians)
- BfArM, DiGA directory (German digital health applications)
- G-BA Innovation Fund, PSY-KOMO project, Annex 15: overview of DiGAs (2026)
Open in the database – with search, filters and comparison (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-11-07.